Long-Term Effects of a Long-Acting β2-Adrenoceptor Agonist, Salmeterol, on Airway Hyperresponsiveness in Patients with Mild Asthma
- 22 October 1992
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 327 (17) , 1198-1203
- https://doi.org/10.1056/nejm199210223271703
Abstract
Asthma is characterized by hyperresponsiveness of the airways to bronchoconstrictive stimuli. Long-acting β2-adrenoceptor agonists have been introduced as a new therapeutic approach, but there is growing concern about whether control of asthma may deteriorate with the regular use of these agents. We investigated the long-term effects of the β2-agonist salmeterol on bronchodilation and on airway hyperresponsiveness to the bronchoconstrictive agent methacholine in mild asthma. In a parallel, double-blind study, 24 patients with mild asthma were randomly assigned to treatment with either inhaled salmeterol (50 μg, twice daily) (n = 12) or placebo (n = 12) during an eight-week trial. Methacholine challenge was performed before, during, and after the treatment period. Methacholine responsiveness was measured as the provocative concentration (PC20) that caused a 20 percent decrease in the forced expiratory volume in one second (FEV1). There was a significant increase in FEV1 one hour after the inhalation of salmeterol (P = 0.006), which did not differ significantly on days 0, 28, and 56 of the treatment period (increase, 9.8, 9.4, and 8.8 percent of predicted FEV1, respectively; P = 0.91). On the first treatment day, salmeterol afforded significant protection against methacholine-induced bronchoconstriction, as shown by a 10-fold increase in the PC20 as compared with the value at entry (P20 was significantly attenuated (P20 was not significantly different from the value before treatment (P = 0.15). Regular treatment of patients with mild asthma with salmeterol leads to tolerance to its protective effects against a bronchoconstrictor stimulus, in this case inhaled methacholine, despite well-maintained bronchodilation. This finding raises concern about the effectiveness of prolonged therapy with long-acting β2-adrenoceptor agonists in asthma. (N Engl J Med 1992;327:1198–203.)Keywords
This publication has 30 references indexed in Scilit:
- The effect of inhaled salmeterol on methacholine responsiveness in subjects with asthma up to 12 hoursJournal of Allergy and Clinical Immunology, 1992
- Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand? A randomised controlled study.BMJ, 1991
- Protection against allergen-induced asthma by salmeterolThe Lancet, 1990
- A New Approach to the Treatment of AsthmaNew England Journal of Medicine, 1989
- Formoterol fumarate, a new β2‐adrenoceptor agonistAllergy, 1989
- Salmeterol, a new long acting inhaled beta 2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients.Thorax, 1988
- Effect of long-term treatment with inhaled corticosteroids and beta-agonists on the bronchial responsiveness in children with asthmaJournal of Allergy and Clinical Immunology, 1987
- The origin of airway hyperresponsivenessJournal of Allergy and Clinical Immunology, 1986
- PrefaceJournal of Allergy and Clinical Immunology, 1986
- Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: A comparison between budesonide and terbutalineJournal of Allergy and Clinical Immunology, 1985